CORRIGENDUM TO "ADJUVANT IMMUNOTHERAPY IN OLDER PATIENTS WITH STAGE III AND RESECTED STAGE IV MELANOMA: TOXICITY AND RECURRENCE-FREE SURVIVAL OUTCOMES FROM THE DUTCH MELANOMA TREATMENT REGISTRY" [EUR. J. CANCER 212, 2024, 115056].
Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].
Show more authors
+ 21
A Özkan
E Kapiteijn
F van den Bos
M J B Aarts
F W P J van den Berkmortel
C U Blank
M Bloem
W A M Blokx
M J Boers-Sonderen
J J Bonenkamp
A J M van den Eertwegh
J W B de Groot
J B Haanen
C E Holtslag
G A P Hospers
D Piersma
R S van Rijn
A M Stevense-den Boer
K P M Suijkerbuijk
A A M van der Veldt
G Vreugdenhil
M W J M Wouters
J E A Portielje
N A de Glas
More about this publication
European journal of cancer (Oxford, England : 1990)